Improving the arthritis component of the SLEDAI-2K
- PMID: 39700424
- PMCID: PMC12107061
- DOI: 10.1093/rheumatology/keae695
Improving the arthritis component of the SLEDAI-2K
Abstract
Objective: To propose a new definition for SLEDAI arthritis informed by imaging.
Methods: We performed a planned secondary analysis of observational data from a multicentre study evaluating SLE patients with inflammatory joint pain (swelling not required) using various clinical instruments, laboratory tests and ultrasound. For SLEDAI arthritis, assessors (blinded to ultrasound) were asked which of the glossary terms for arthritis in any version of the SLEDAI drove their decision to score for arthritis. These definitions were tested against ultrasound and other clinical variables. ROC analysis was used to test optimal joint count thresholds.
Results: A total of 78/133 patients had arthritis on SLEDAI-2K. In 21/78, clinician-observed swelling was not a reason for scoring (tenderness: 16/21; reported swelling between visits: 4/21; both of these: 1/21). No patient was scored for warmth or erythema alone. In total, 57 (73.1%) patients were scored for SLEDAI arthritis due to observed swelling, 90% had abnormal ultrasound (PPV = 90%, 95%CI: 79, 94). Of 21 patients with SLEDAI arthritis without observed swelling, 48% had abnormal ultrasound (PPV: 48%, 95%CI: 31, 67). Patients with SLEDAI arthritis with swelling had higher ESR, physician MSK-VAS, patient early morning stiffness (EMS)-VAS and IgG compared with other patients. Optimal sensitivity and specificity for ultrasound synovitis was 1 swollen joint using Youden's criteria.
Conclusions: Our data suggest that the definition of arthritis in SLEDAI be modified to: 'Inflammatory musculoskeletal pain (symmetrical small joint distribution), with one or more clinically swollen joints witnessed on examination, that is not explained by another arthropathy'.
Keywords: biomarkers; clinical trials and methods; outcome measures; systemic lupus erythematosus; ultrasound.
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
References
-
- Zayat AS, Mahmoud K, Md Yusof MY et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology 2019;58:304–12. - PubMed
-
- Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythmatosus. Curr Opin Rheumatol 2017;29:486–92. - PubMed
Publication types
MeSH terms
Grants and funding
- University of Benghazi
- Leeds Biomedical Research Centre
- UK Research and Innovation
- 21593/Centre for Adolescent Rheumatology Versus Arthritis
- CS-2013-13-032/Clinician Scientist
- NHS
- 204825/Z/16/Z/Institutional Strategic Fund
- AstraZeneca
- Leeds Teaching Hospitals NHS Trust
- MRC
- National Institute for Health and Care Research
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
